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ABSTRACT
The most common and improved bioavailable route for protein and peptide drugs is injectable route. These drugs are generally preferred to 
give in invasive route to get high bioavailability though possessing disadvantages and the major one is patient non- compliance. Hence, various 
non-invasive route of administration has been under research for these drugs to fetch more advantages. Although bioavailability is a major problem 
with non-invasive route such as oral, nasal, ocular, transdermal, rectal, colon, and vaginal route, these routes have been preferred compared to 
existing invasive one. Many researches have been conducted in this area, but achieving success is significantly challenging. The nasal delivery has 
been successfully exploited for vaccines compare to all other non-invasive drug delivery system. Currently, only molecule to reach market is oral 
cyclosporine. The present review aims to discuss the potential non-invasive routes of protein and peptide drug delivery. The factors which will affect 
drug permeation, and the bioavailability of proteins administered through these routes is also emphasized.
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INTRODUCTION
In recent years, proteins and peptides have emerged as promising 
therapeutic agents.
There are various problems associated with these agents. The 
problems are selecting a route of delivery and preparing a 
bioavailable formulation of these biopharmaceutical agents. 
Parenteral route is the common preferred route of delivery for 
parenteral drug delivery system. There are many disadvantages with 
this route of administration which is poor patient compliance and 
pain at the site of administration despite 100% bioavailable. Oral 
drug delivery of these drugs undergoes acid hydrolysis and extensive 
first-pass metabolism and degradation by enzymes. Hence, protein 
drugs other than parenteral route possess many disadvantages and 
very challenging for the pharmaceutical scientist to formulate a 
bioavailable non-invasive route for these drugs. The non-invasive 
routes under research are mucosal, transdermal, nasal, ocular, 
pulmonary, rectal, vaginal, buccal, and sublingual offer effective 
alternatives for systemic drug delivery.
Potential mechanisms of transport across cells are passive paracellular, 
passive transcellular, facilitated transcellular, active carrier-mediated, 
and transcytosis. The cellular barrier for each non-invasive delivery 
route is more complex, and a lot of manipulation is required to overcome 
the problems associated with permeation (Fig.1).
ORAL DELIVERY
Oral route is preferred over any other route because of good patient 
compliance and acceptance. This is the most preferred route for chronic 
ailments. Designing and formulating protein and peptide drug delivery 
system for the gastrointestinal (GI) route are a challenge because of 
the unfavorable conditions posed by it such as pre-systemic enzymatic 
degradation and poor membrane permeability.
Barriers for oral absorption
The barrier that prevents the entry of protein or peptide drugs into 
the systemic circulation is intestinal epithelial tight junctions. The 
major problems involved in oral delivery of proteins can be given 
as denaturation of proteins due to acidic environment in stomach, 
degradation of proteins in stomach and intestine due to proteolytic 
enzymes, intestinal wall which is impermeable to macromolecules, 
mucin barrier which is formed by mucus that is secreted by goblet cells, 
and intestinal transit time [1,2].
Enzymatic barriers
Most of the proteins are known not to be absorbed in humans 
as intact forms. They are usually broken down into amino 
acids or di- and tri-peptides first in the GI tract (GIT). The four 
peptidases secreted by the pancreas, that is, trypsin, chymotrypsin, 
carboxypeptidase, elastase, convert proteins, and polypeptides to 
oligopeptides [3].
Luminal degradation of proteins is up to 20% of the total degradation 
in the small intestine. The rest of the degradation occurs on contact 
with the brush border membrane or after entry into the cell. Brush 
border peptidases such as amino oligopeptidase, aminopeptidase, 
and dipeptidyl aminopeptidase then breakdown the oligopeptides 
to amino acids (up to 70%) and di- and tri- peptides (up to 
30%) [3,4].
The above-mentioned enzymatic barriers must be overcome to 
improve oral absorption of protein and peptide drugs from the GIT. 
This may be possible to achieve to some extent using enzyme inhibitors 
or by chemical modification or by other approaches has been given in 
Table 1. GI absorption of peptides and peptide-like drugs is given in 
Table 2.
Bioavailability
Captopril, lisinopril, and enalapril have good oral bioavailability due to 
their low-molecular weight and their ability to inhibit tissue carboxyl 
peptidases [11]. Cyclosporine is a cyclic peptide with a number of 
methylated amino acid residues and is resistant to hydrolysis and 
therefore has good bioavailability [12]. Some protease inhibitors and 
absorption enhancers have been coadministered with peptide drugs 
to enhance their oral absorption. A good example is oral arginine-
vasopressin. To produce a 50% reduction in urine flow, in the rat, 
an oral dose of about 3500 pmol was required. When the drug was 
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coadministered with aprotinin, a protease inhibitor, the oral dose was 
reduced to 1000 pmol [13].
NASAL DELIVERY
Barriers for nasal absorption
Nasal route provides advantages such as having larger surface area for 
absorption and almost closer to intravenous route of bioavailability 
is achievable. The lipophilicity of the molecule plays major role in 
absorption. The central nervous system can be targeted through this 
route with improved efficacy. For vaccines, nasal route is the most 
preferred route of delivery [14].
Nasal mucosa and nasal epithelium
The nasal epithelium consists of loosely packed cells with high 
permeability and vasculature. Passive diffusion, carrier-mediated 
transport, and transcytosis are the transportation mechanisms, 
through which nasal absorption is achieved [15,16]. Molecular 
weight plays a major role in reducing the absorption of compounds 
such as desmopressin, insulin, and human growth hormones. Low 
molecular weight compounds permeate at a faster rate. Pgp efflux 
transporters also another actor influences absorption through nasal 
epithelium [17-19].
Mucociliary clearance
The major barrier for nasal delivery is nasal mucociliary clearance 
(NMC). The residential time of many drugs has reduced to greater 
extent [20]. The NMC is a natural defense mechanism of the body to 
expul the foreign objects thus preventing the absorption of drug 
molecules. Antihistaminic drugs, beta blockers, general anesthetics, 
cocaine, etc., arrest the mucociliary clearance. Thus, NMC reduces the 
nasal bioavailability of drugs [21-29]. Various approaches for nasal 
delivery have been given in Table 3.
Table 1: Approaches to increase the oral bioavailability
Approach Example Outcome References
Absorption enhancers Detergents, bile salts, fatty acids, chitosans, 
acylcarnitine, alkanoyl choline, N-acetylated 
α‑amino acids, N‑acetylated non‑α‑amino acids
Temporarily disturb intestinal barrier to 
improve the permeation
[5]
Enzyme inhibitors Trypsin, chymotrypsin, carboxypeptidases, 
aprotinin, pancreatic inhibitors






Conjugation with polymer PEG or ligands like 
transferring
1, 3-dilpalmitoylglycerol
Affects receptor binding capacity and decreases 
rate of clearance from systemic circulation





Types: Anionic, cationic, non-ionic, amphoteric, 
thiomres, dendrimers, synthetic glycol polymers, 
etc., ex: chitosan








S/O/W emulsion (surfactant - insulin complex is 
dispersed into oil phase)
Microspheres of poly (methacrylic-g-ethylene 
glycol)
Polystyrene, chitosan, PLA-PGA
PEGylated liposomes, and mucin containing 
liposomes
Chemical and enzymatic breakdown protection 
in lumen
Protects over the influence of the PH variability 
through the stomach to intestine
Less sensitivity to enzymes




Fig. 1: A schematic illustration of potential mechanisms of transport across the cellular barrier in non-invasive routes of drug delivery 
systems. (A) Passive transcellular, (B) passive paracellular, (C) facilitated transcellular or active carrier mediated, (D) transcytosis
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Drug metabolism
Even though nasal route provides low metabolic environment, 
metabolism of proteins and peptide molecules in nasal cavity is a major 
barrier for bioavailability [34-35]. The main enzymatic barrier present 
in the nasal mucosa is cytochrome P450 enzymes. Cytochrome P450 
is present in both respiratory and olfactory mucosa, thus reducing 
both nose-to-blood and nose-to-brain transport of drugs[36]. Low 
bioavailability of protein and peptide drugs is obvious by the presence 
of various proteolytic enzymes such as exopeptidase (mono and 
diamino peptidase) and endopeptidase (serine, cysteine, and aspartic 
peptidase)[37].
OCULAR DELIVERY
Ocular route is mainly used for the treatment of ocular 
inflammation, corneal wounds, and glaucoma. The administration 
of biopharmaceuticals through eye is complicated by the normal 
processes of blinking, tearing, and drainage from the eye which wash 
out the drugs which are administered.
Drug absorption
The cornea is composed of three major layers: Two boundary 
cellular layers, the epithelium, the endothelium, and the stroma 
(a thick connective tissue) in between. The corneal epithelium is a 
non-keratinized stratified squamous epithelium, 5-6 cell layers in 
thickness (Fig.2).
The conjunctiva consists of a stratified squamous epithelium, 
overlying a loose, highly vascular connective tissue, and the 
Table 2: GI absorption of peptides and peptide-like drugs
Compound Percentage of 
absorption
References 
Dietary di- and tri-peptides 5-50 [7]
Aminocephalosporins >50 [8]
Enalapril >50 [9]
Dietary tetrapeptides ≈5 [10]




Table 3: Approaches for nasal delivery
Approach Description References
Nasal mucoadhesive Ideal choice of delivery system increases the nasal residence time
e.g.: 98% bioavailability was achieved for apomorphine by mucoadhesive polymers 
such as polyacrylic acid, carbopol, and CMC
[30]
Enhanced nasal blood flow By increasing the concentration gradient for passive diffusion of peptide drugs 
Nasal blood flow can be increased by vasoactive agents such as histamine, 
prostaglandin E1, and beta-adrenergic agonists
[31]
Novel drug delivery systems 
1. Microspheres
2. Vesicles
Absorb water into the sphere matrix, resulting in swelling and gel formation, this 
increase the residential time of the drug in the mucosa
Materials used to construct microspheres include starch, dextran, albumin, 
hyaluronic acid, carbopol, and chitosan. For example: Dextran used for insulin, 
octreotide, and nicotine
The amphiphilic nature of liposomes is well characterized for favorable permeation 
of drugs through biological membranes
The comparative pharmacokinetics in rats showed high permeability of liposome 
pre-treated with permeation enhancer than solution form containing the same 
quantity of permeation enhancer
[32,33]
pH modification At isoelectric point proteins and peptides usually have less solubility; by adjusting 
pH its solubility can be increased. For example: DDAVP exhibits good solubility at 
pH 4.0
[21]
substantia propria [38]. The conjunctival epithelium is continuous 
with the corneal epithelium at the corneoscleral limbus. A drug 
administered topically on the percorneal area comes into contact 
with the corneal and conjunctival epithelia followed by absorption 
by ocular tissue. This absorbed drug enters into the systemic 
circulation by various processes like corneal absorption which is 
through adjacent ocular tissues because it is avascular. Conjunctiva 
is highly perfused and most of the absorbed drug enters to the 
systemic circulation. The nasolacrimal secretion also another 
process through which drug is lost. The enzymes such as neutral 
protease and aminopeptidase also cause destruction of proteins and 
peptides. Some novel approaches such as cyclodextrin complexes 
of cyclosporin have increased the biovailabilty through corneal 
tissues [39-42].
TRANSDERMAL DELIVERY
Transdermal drug delivery provides lot of advantages due to large 
surface area which can enhance the flux of the drugs with the use of 
appropriate enhancers. The stratum corneum (SC) is the major barrier. 
It also avoids first-pass metabolism. This route high patient compliant 
route and any time the drug action can be terminated [43].
Barrier for transdermal delivery
The major barrier of skin permeation is SC the outer most layer. Skin 
allows only passive diffusion of drugs. There are ideal properties 
of a drug to possess to permeate through the skin. The ideal log P, 
molecular weight, melting point, solubility, and dose of the drug 
influences the permeation through skin. Chemical permeation 
enhancers play major role as passive enhancement of drugs through 
skin [44].
Skin barrier function
SC and routes of passive permeation: The major barrier is SC, 
the thin, outermost layer of the epidermis [45]. The SC consists 
of several layers of protein-filled corneocytes (i.e., terminally 
differentiated keratinocytes) embedded in an extracellular lipid 
matrix. Passive permeation across the SC is believed to occur 
primarily through the intercellular lipid pathway (Fig. 3a) which 
constitutes the only continuous phase through the SC, appendageal 
transport through hair follicles, and sweat glands is another 
potential route, these structures offering “shunt” pathways across 
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the continuity of the SC (Fig. 3b). Visualization of appendageal 
transport has been accomplished both for passive diffusion and 
for percutaneous transport enhanced by one means or another 
(e.g., iontophoresis) [46,47]. A third possible route across the SC is 
the transcellular path (Fig. 3c).
Approaches for transdermal delivery
Several approaches have been explored that provide additional 
driving force in the form of electrical (iontophoresis) [48] or 
ultrasound (sonophoresis) [49] energies, structural perturbation 
of SC (e.g., electroporation, thermal microporation, microneedles), [50] 
penetration enhancers, [51,52] or a combination of these strategies.
Iontophoresis
To a few square centimeters of skin, a small amount of physiologically 
accepted current is applied to drive drug molecules into and across the 
skin. Iontophoretic delivery is achieved by 2 ways of electrorepulsion 
and electroosmosis [44].
Electrorepulsion
Delivery of charged molecule across the skin is possible due to repulsion 
between same charges, when a charged molecule is placed under an 
electrode of same polarity.
Electroosmosis
Skin is negatively charged; transport of positively charged drugs is 
possible. Under the influence of electric current, net flow of water from 
anode to cathode occurs which is called electroosmosis.
Iontophoretic study of some of harmones such as LHRH showed 
increased permeation following SC injection [53-55].
Fig. 2: Diagrammatic representation of cross section of cornea
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Electroporation
Application of 100-1000 V to enhance the permeability of drugs through 
skin opens the pathway for aqueous route. Movement of ions followed 
by enhanced diffusion and electrodiffusion is the possible mechanism 
to enhance the delivery through skin.
Sonophoresis
Use of low-frequency ultrasound in the range of 1-3 MHZ for delivery of 
molecules across the skin is called sonophoresis. Piezoelectric crystal 
which is made of lead zirconate is the main component of equipment, 
will convert the electrical energy into mechanical energy giving raise to 
acoustic waves or ultra sounds [56].
Formulation approaches
To enhance the skin permeability of protein and peptides, 
novel strategies are followed. Use of protease inhibitors, or 
formulations such as  liposomes, niosomes found to enhance the 
skin permeation. These studies were conducted only on animals 
and not done on human models. Vesicular drug delivery systems 
such as ultradeformable vesicles like transfersomes can enhance 
the creation of hydrophilic pathways. Stearylamine and sodium 
cholate are used as edge activators. This approach has also been 
successfully demonstrated with other polypeptides such as 
interferons a, b, and g, calcitonin, and superoxide dismutase in pre-
clinical experiments [57-59].
COLONIC DELIVERY
The colon has received considerable attention as a possible delivery 
site for protein and peptide drug delivery compared to other possible 
oral routes because enzyme activities are significantly lower when 
compared to small intestine, the residence time in colon is longer, the 
bacteria present in colon secrete many enzymes which act as triggers 
for colon-specific drug delivery, and the microflora degradation 
mechanism has been used as a tool for the site-targeted delivery of 
peptide and protein drugs.
Barrier for colonic absorption
Colonic absorption of protein and peptide drugs administered orally 
are seriously restrained by diffusional barriers (unstirred layers and 
mucosal permeability) as in the case of small intestine, but more 
importantly the inhibition is due to metabolism which occurs in the 
lumen, brush border, and at the cytosol level [60].
Colonic absorption
The lack of organic nutrient transporters may limit the potential 
for drug design with respect to carrier-mediated transport across 
the colon. The active transport pathways of the colon have been 
reviewed [61]. The transmucosal and membrane potential differences 
may be significant in the absorption of ionized or ionizable drugs [62]. 
Colon offers less barrier to macromolecules than small intestine, 
therefore, it is suitable for both protein and peptide absorption. The 
bulk water absorption in this region of the intestine provides scope 
for solvent drag and possibly improved drag and possibly improved 
drug absorption [63].
Approaches for colonic delivery
Peptide and protein drugs are coated with azoaromatic groups to 
form an impermeable film to protect them from digestion in the 
stomach and small intestine. When the polymer-coated peptide and 
protein drugs reach the colon, the colonic bacteria cleave the azo 
bonds and break the polymer film, releasing the drugs into the lumen 
of the colon for absorption. This polymeric system was demonstrated 
to protect and deliver orally administered insulin and vasopressin in 
rats [13]. Other approaches for colonic delivery have been given in 
Table 4.
Table 4: Approaches for colonic delivery
Polymeric approach Mechanism Polymers used References
Enteric coating polymers Dissolve in the pH range 4.8-7.0 Eudragit L100 & S 100, HPMC pthalate [64]
Timed release polymers Retard the release of drug long 
enough to reach large intestine
HPMC, polysaccharides such as pectin and calcium pectinate 
ethyl cellulose, natural polymers
[65]
Biodegradable polymers Azo reduction causes degradation of 
polymer
Copolymers of styrene and hydroxylethyl methacrylate 
cross-linked with divinilazobenzene derivative. Polylactic acid, 
polyglycolic acid
Saccharidic polymers Increase in the porosity of the film 
as a result of enzymatic degradation
Mono-, di-, or oligo saccharides are treated with synthetic 
polymers eg; Guar gum - alactomannans+Eudragit, dextran 
hydrogels cross-linked with diisocynate
[66]
Table 5: An overview of non-invasive protein and peptide drug delivery
Route Enzymatic 
activity level
Barriers Examples of drugs
Oral More Enzymes, rapid post- absorptive clearance, physical instabilities such as 
adsorption and aggregation
Cyclosporine, enalapril
Colonic Less High concentration of anaerobic bacteria and absence of villi and 
microvilli
Tissue necrosis factor, proleukin, and 
epidermal growth factor
Nasal Less Mucus secretions, mucociliary clearance, extent of absorption varies 
with mucus secretions, rhinitis
Desmopressin, oxytocin, and buserelin
Ocular Less Enzymatic degradation by neutral protease and aminopeptidase, 
nasolacrimal secretions
Enkephalins, epidermal growth factor, 
and mesodermal growth factor
Transdermal Less Lipophilicity of SC, low permeation for proteins due to large mol. wt. 
and hydrophilicity
Insulin, salson calcitonin, LHRH
Vaginal Less Changes in thickness and porosity of the vaginal epithelium, presence of 
thick cervical mucus due to menstruation cycle
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Drug metabolism
Drug metabolism in the colon is caused by the host enzymes in the 
epithelial cells or by the microbial enzymes in the gut flora. Metabolic 
activities in the wall of the colon can be attributed to enzymes such as 
cytochrome P450, esterases, amidases, and various transferases [67]. 
The colonic mucosa resembles the small intestinal mucosa with respect 
to the spectrum of metabolizing enzymes. However, the total metabolic 
capacity of the colonic wall is inferior, because the mucosal mass in 
the lower part of the intestine is several times smaller than that in the 
upper part.
VAGINAL DELIVERY
Vaginal administration of peptide and protein drugs which are used 
specifically for the treatment of female-related conditions is a favorable 
alternative to parenteral administration.
Vaginal barrier for absorption
The vaginal wall consists of three main layers: An outer fibrous layer, a 
middle muscular layer, and an epithelial layer. The vaginal epithelium 
is a stratified, squamous epithelium which rests on a lamina propria. 
The surface area of the vagina is increased by numerous folds in the 
epithelium and by microridges covering the epithelial cell surface [68].
In common with other mucosal routes, drugs administered vaginally 
will be transported across the vaginal membrane by a number of 
different mechanisms (Fig. 4):
i. By diffusion through the cell due to a concentration gradient 
(transcellular route);
ii. By a vesicular or receptor-mediated transport mechanism; or
iii. By diffusion between the cells through the tight junctions 
(intercellular route).
Advantages
Despite traditionally being a site for the delivery of locally acting 
drugs, the vagina has great potential for the systemic absorption of 
drugs due to its large surface area, rich blood supply, and permeability 
to a wide range of compounds, including peptides and proteins [69]. 
This route provides avoidance of first-pass metabolism, GI effects, 
side effects at GIT. Steroids used in hormone replacement therapy 
or for contraception have been administered vaginally to reduce the 
possibility of hepatic side-effects, associated with oral route [70]. 
Another advantage is the possible self-insertion and removal of the 
dosage form [71].
Disadvantages
The main disadvantages include the gender specificity, personal 
hygiene, local irritation, sexual intercourse, and cultural sensitivity.
Factors affecting the vaginal absorption of drugs
The thickness and porosity of vaginal epithelium may affect vaginal 
absorption. Menstrual cyclic changes may be one of the reasons for this. 
The presence of moisture helps in absorption. The major barrier for 
absorption is thick cervical mucous and also the pH of the secretion [71].
Drug absorption
Animal studies have shown changes in the intravaginal absorption of 
insulin and TSH which may be due to menstrual cycle. Insulin being a 
hydrophilic in nature may have enhanced absorption due to thinness 
of epithelium. Absorption enhancers may help in enhancing the 
absorption [72-74].
Initial work with leuprolide found greater potency in rats through 
vaginal administration over rectal, nasal, and oral administration [75]. 
Enhancement of absorption by organic acids (citric, succinic, tartaric, 
and glycocholic) increased bioavailability by 20%.
Good absorption of some of the protein drugs such as estradiol and 
progesterone found due to thin atrophic vaginal epithelium [76].
Approaches for vaginal administration
1. Hydrogel slabs: The vaginal slabs are produced from polyethylene 
glycol -hexane trioldiisocyanate hydrogel and form a tridimensional 
lattice which swells when exposed to water and in this way it can be 
Fig. 4: Schematic representation of vaginal membrane as transport barrier
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loaded with drug. After drying, the drug is trapped in the hydrogel 
matrix in a near dry state which results in increased stability of the 
drug. The hydrogel swells and the drug is released, after vaginal 
administration [76].
2. Microbicidal gel: Microbicidal gel containing monoclonal human 
antibodies is used for topical immunization, for protecting genital 
skin, and epithelia from HIV and STIs pathogens [69].
3. Mucoadhesive delivery systems: Polycarbophil, hydroxypropyl 
cellulose, and polyacrylic acid are the bio-adhesive polymers 
employed for intravaginal formulations. Hyaluronic acid-based 
intravaginal delivery of calcitonin, a polypeptide used in the 
treatment of post-menopausal osteoporosis, has shown promise for 
intravaginal administration of drugs for systemic effect [69].
RECTAL ROUTE
Rectal delivery of peptide and protein drugs is another very active area 
of research.
Advantages of rectal protein and peptide drug delivery
Rectal route has less protease activity, partially avoids first-pass 
metabolism. This route also facilitates potential for absorption 
through lymphatic system. This route can be exploited for controlled 
release drug delivery system because of its relatively large surface 
area [77,78].
Barriers for rectal absorption
The barriers of drug absortion are apical membrane, cell body, and 
tight junctions. The enzymatic barrier includes the presence of 
peptidases [79].
Approaches for rectal delivery
Absorption enhancers play a major role in improving rectal absorption. 
The absorption enhancers, increases the membrane fluidiry, increases 
the size of the intercellular space, and enhances the solubility of 
mucosal membrane thereby increasing the water penetration. This also 
reduced the viscosity of mucus layer.
The various absorption enhancers include sodiumtaurodihydrofusidate, 
sodium 5-methoxy salicylate, enamine derivatives, and sodium caprate. 
Some of the protease inhibitors are also can be used as enzyme 
inhibitors, which includes aprotinin, trypsin inhibitors, bacitracin, 
puromycin, bestatin, and bile salts [80].
Drug absorption
Although extensive villi and microvilli are not present in the rectum 
tissue, sufficient surface area is present to allow absorption of readily 
permeable drugs. There is an extensive motility small intestine 
incontrast to rectum enables high concentration gradient.
Together with a limited fluid volume in the lower colon, typically 
2-3 ml of inert mucous fluid in the absence of fecal material, the static 
environment of the rectum and lower colon provides an area for 
maintaining significantly higher drug concentrations than is readily 
achievable in the small intestine.
Significant rectal absorptions of growth hormone have also been 
demonstrated with the help of absorption enhancing agents. The 
apical membranes of the small intestine epithelial cell layer express 
high levels of membrane-associated or membrane-bound enzymes, 
such as peptidases and saccharidases, which are not present in 
high amounts on the apical surfaces of epithelial cells in the rectal 
cavity [81-84].
An overview of non-invasive protein and peptide drug delivery is given 
Table 5 and the available marketed formulations are given in Table 6.
CONCLUSION
With the advent of newer molecules in pipeline, large number of 
proteins and peptides are to be available in coming years. Injectable 
protein and peptide drugs possess a lot of disadvantages and non-
invasive drug delivery become choice of the day. Although lot of 
intricacies involved in understanding the non-invasive delivery routes, 
scientists have started devising a novel technology to administer these 
drugs with improved bioavailability. Although there is a limitation of 
the current non-invasive route of protein and peptide drug delivery 
system, continued research may enable the cost-effective, useful, and 
patient compliant biopharmaceuticals.
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